Efficacy observation of 125 I seed implantation therapy for locoregional recurrent and metastatic breast cancer
10.3760/cma.j.issn.0253-3766.2016.06.013
- VernacularTitle:125 I放射性粒子治疗局部复发或转移乳腺癌的疗效观察
- Author:
Fuxiang YI
1
;
Yinghua YU
;
Changyuan WEI
;
Weiping YANG
;
Qinghong QIN
;
Qixing TAN
;
Qinguo MO
;
Zhen HUANG
;
Bin LIAN
Author Information
1. 广西医科大学附属肿瘤医院乳腺外科
- Keywords:
Breast neoplasms;
Recurrence;
Neoplasms matastatic;
125 I seed;
Brachytherapy
- From:
Chinese Journal of Oncology
2016;38(6):472-475
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the efficacy and side effects of 125 I seed implantation for locoregional recurrent and metastatic breast cancer, and to discuss its role in the comprehensive therapy of breast cancer. Methods Forty?three patients with locoregional recurrent or metastatic breast cancer were included in this study. They received 125 I seed implantation and were followed up to evaluate the efficacy and adverse reactions of the treatment. Results Among 54 lesions in the 43 cases, there were complete response (CR) in 39, partial response (PR) in 13, stable disease (SD) in 2 patients, with a response rate of 96.3%. All 17 cases with local pain achieved pain relief. With a median follow up of 36 months ( range 14 to 60 months) ,the 1?, 3?, and 5?year local control rate was 85.2%, 53.7% and 1.9%, and the 1?, 3?, and 5?year survival rate was 95. 3%, 67. 4% and 37. 2%, respectively. No serious radiotherapy side effect was observed. Conclusion In patients with unresectable locoregional recurrent or metastatic breast cancer, 125 I seed implantation shows proved efficacy and few complications, and can be an important treatment option.
